Preclinical evaluation of the theranostic potential of ⁸⁹Zr/¹⁷⁷Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is one of the most lethal malignant tumors among women, characterized by high invasiveness, high heterogeneity, and lack of specific therapeutic targets such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Trophoblast cell-surface antigen-2 (TROP-2) is a transmembrane glycoprotein over-expressed in 80% of TNBC patients and is associated with the occurrence, progress, and poor prognosis of TNBC. The TROP-2 targeted immunoPET imaging allows non-invasive quantification of the TROP-2 expression levels of tumors, which could help to screen beneficiaries most likely to respond to SG and predict the response. This study aimed to develop a ⁸⁹Zr/¹⁷⁷Lu-radiolabeled anti-TROP-2 ant

SUBMITTER: Wu Y 

PROVIDER: S-EPMC10776551 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature